Difference between revisions of "IgG4-related systemic diseases"
Jump to navigation
Jump to search
| (6 intermediate revisions by the same user not shown) | |||
| Line 14: | Line 14: | ||
Features:<ref name=pmid28701054>{{cite journal |authors=Abraham M, Khosroshahi A |title=Diagnostic and treatment workup for IgG4-related disease |journal=Expert Rev Clin Immunol |volume=13 |issue=9 |pages=867–875 |date=September 2017 |pmid=28701054 |pmc=5896560 |doi=10.1080/1744666X.2017.1354698 |url=}}</ref> | Features:<ref name=pmid28701054>{{cite journal |authors=Abraham M, Khosroshahi A |title=Diagnostic and treatment workup for IgG4-related disease |journal=Expert Rev Clin Immunol |volume=13 |issue=9 |pages=867–875 |date=September 2017 |pmid=28701054 |pmc=5896560 |doi=10.1080/1744666X.2017.1354698 |url=}}</ref> | ||
*At least 10 IgG4 +ve plasma cells.† | *At least 10 IgG4 +ve plasma cells.† | ||
*>40% of plasma | *>40% of [[plasma cell]]s IgG4 +ve. | ||
Note: | Note: | ||
*† Minimum number dependent on anatomical site.<ref name=pmid28701054/> | *† Minimum number dependent on anatomical site.<ref name=pmid28701054/> | ||
** Lymph node: 100 (or 50) plasma cells/HPF, where 1 HPF ~ 0.196 mm*mm and 3 HPFs (0.588 mm*mm) are assessed.<ref>{{cite journal |authors=Cheuk W, Chan JK |title=Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity |journal=Semin Diagn Pathol |volume=29 |issue=4 |pages=226–34 |date=November 2012 |pmid=23068302 |doi=10.1053/j.semdp.2012.07.001 |url=}}</ref> | |||
==Sign-out== | |||
===Not present=== | |||
<pre> | |||
The provided clinical history is noted. Plasma cells are not readily apparent (<10 plasma cells/0.196 mm*mm). | |||
</pre> | |||
==See also== | |||
*[[Plasma cells]]. | |||
*[[HPFitis]]. | |||
==References== | ==References== | ||
Latest revision as of 14:45, 3 March 2022
The IgG4-related systemic diseases, also IgG4-related diseases, are diseases characterized IgG4 positive plasma cells and fibrosis.[1]
- Lymphoplasmacytic sclerosing pancreatitis - a type of autoimmune pancreatitis.
- Retroperitoneal fibrosis.[2]
- Riedel's thyroiditis.
- Inflammatory pseudotumour,[2] also known as inflammatory myofibroblastic tumour (IMT); probably only a subset of IMT.[3]
- Sclerosing cholangitis[2] (IgG4-associated cholangitis[4]).
- Autoimmune pancreatitis (lymphoplasmacytic sclerosing pancreatitis).
- Others.
Microscopic
Features:[5]
- At least 10 IgG4 +ve plasma cells.†
- >40% of plasma cells IgG4 +ve.
Note:
- † Minimum number dependent on anatomical site.[5]
- Lymph node: 100 (or 50) plasma cells/HPF, where 1 HPF ~ 0.196 mm*mm and 3 HPFs (0.588 mm*mm) are assessed.[6]
Sign-out
Not present
The provided clinical history is noted. Plasma cells are not readily apparent (<10 plasma cells/0.196 mm*mm).
See also
References
- ↑ Khosroshahi, A.; Stone, JH. (Jan 2011). "A clinical overview of IgG4-related systemic disease.". Curr Opin Rheumatol 23 (1): 57-66. doi:10.1097/BOR.0b013e3283418057. PMID 21124086.
- ↑ 2.0 2.1 2.2 Kamisawa, T.; Okamoto, A. (Jul 2008). "IgG4-related sclerosing disease.". World J Gastroenterol 14 (25): 3948-55. PMID 18609677.
- ↑ Saab, ST.; Hornick, JL.; Fletcher, CD.; Olson, SJ.; Coffin, CM. (Apr 2011). "IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?". Mod Pathol 24 (4): 606-12. doi:10.1038/modpathol.2010.226. PMID 21297584.
- ↑ Barnabas, A.; Chapman, RW. (Feb 2012). "Primary sclerosing cholangitis: is any treatment worthwhile?". Curr Gastroenterol Rep 14 (1): 17-24. doi:10.1007/s11894-011-0230-8. PMID 22124849.
- ↑ 5.0 5.1 Abraham M, Khosroshahi A (September 2017). "Diagnostic and treatment workup for IgG4-related disease". Expert Rev Clin Immunol 13 (9): 867–875. doi:10.1080/1744666X.2017.1354698. PMC 5896560. PMID 28701054. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896560/.
- ↑ Cheuk W, Chan JK (November 2012). "Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity". Semin Diagn Pathol 29 (4): 226–34. doi:10.1053/j.semdp.2012.07.001. PMID 23068302.